Cerenome
Diagnostic testing and targeted radiotherapy development for central nervous system cancers.
$3.05
After-hours close+0.01 (+0.33%)
At close$3.04(−1.94%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$0.89 | — | — |
| Aug 2026 | −$0.88 | −$1.31 | −48.9% |
| Aug 2026 | −$0.96 | −$1.31 | −36.5% |
| May 2026 | −$0.85 | −$1.05 | −23.8% |
| Mar 2026 | −$0.80 | −$0.83 | −4.2% |
The latest year is open to everyone — the 4 quarters behind it read with an account. Sign in | |||
| Oct 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | −$0.89 | — | — | $1.4M | — | — |
| Aug 14, 2026 | −$0.88 | −$1.31 | −48.9% | $1.1M | $411.0K | −63.1% |
| Aug 13, 2026 | −$0.96 | −$1.31 | −36.5% | $1.1M | $411.0K | −63.1% |
| May 15, 2026 | −$0.85 | −$1.05 | −23.8% | $974.0K | $1.0M | +5.5% |
| Mar 12, 2026 | −$0.80 | −$0.83 | −4.2% | $1.2M | $1.4M | +10.6% |
The latest year is open to everyone — the 4 quarters behind it read with an account. Sign in | ||||||
| Oct 30, 2025 | ||||||
| May 30, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 14, 2024 | ||||||